By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syndax Pharmaceuticals Inc. 

400 Totten Pond Road
Suite 110
Waltham  Massachusetts  02451  U.S.A.
Phone: 781-419-1400 Fax: 781-419-1420


Start Up

Company News
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round 8/26/2015 6:34:54 AM
Massachusetts' Syndax Banks $80 Million Series C 8/24/2015 6:27:28 AM
Ex-AstraZeneca PLC (AZN) CMO Takes Helm at Tiny Syndax 6/15/2015 6:17:22 AM
Syndax Pharmaceuticals Inc. And Merck & Co. (MRK) To Collaborate On Immuno-Oncology Study Evaluating Entinostat In Combination With KEYTRUDA (Pembrolizumab) In Lung Cancer And Melanoma 3/31/2015 11:28:27 AM
Syndax Pharmaceuticals Inc. To Participate In Two Upcoming Conferences 3/12/2015 11:06:36 AM
Syndax Pharmaceuticals Inc. To Present At 2015 BIO CEO & Investor Conference 2/5/2015 12:28:45 PM
Syndax Pharmaceuticals Inc. Snags $125 Million Deal With Kyowa Hakko Kirin 1/8/2015 7:34:35 AM
Syndax Pharmaceuticals Inc. Release: Entinostat Improves Treatment Outcomes When Combined With Immune Checkpoint Blockade In Preclinical Tumor Models 7/30/2014 8:25:39 AM
Cancer Biotech Syndax Pharmaceuticals Inc. Sets Terms For $60 Million IPO 6/6/2014 6:58:28 AM
Syndax Pharmaceuticals Inc. Announces Presentation Of Entinostat Data In Two Posters At The 2014 American Society of Clinical Oncology (ASCO) Annual Meeting 5/27/2014 6:24:36 AM